<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03014323</url>
  </required_header>
  <id_info>
    <org_study_id>141552-specific aim 2</org_study_id>
    <nct_id>NCT03014323</nct_id>
  </id_info>
  <brief_title>Racial Differences in Vagal Control of Glucose Homeostasis, Chronic Study</brief_title>
  <acronym>RDVCGH</acronym>
  <official_title>Racial Differences in Vagal Control of Glucose Homeostasis, Chronic Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vanderbilt University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Investigators will test the hypothesis that chronic restoration of vagal nerve activity with
      a central acetylcholinesterase inhibitor improves insulin sensitivity and reduces adipose
      tissue oxidation in obese African American Women compared to white women.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Investigators will test the hypothesis that chronic restoration of parasympathetic nervous
      system (PNS) activity with a central acetylcholinesterase inhibitor improves insulin
      sensitivity and reduces adipose tissue oxidation in obese African American women (AAW)
      compared to white women (WW). A cross-over study will be performed in matched cohorts of AAW
      and white women subjected to chronic central acetylcholinesterase inhibition with galantamine
      versus placebo, given orally over a 4-week period. Insulin sensitivity will be measured using
      the gold standard hyperinsulinemic-euglycemic clamp. Adipose tissue will be obtained through
      subcutaneous fat biopsies where F2-isoprostanes will be quantified.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2017</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">November 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>insulin sensitivity</measure>
    <time_frame>4 weeks</time_frame>
    <description>insulin sensitivity will be measured with hyperinsulinemic euglycemic clamps</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">28</enrollment>
  <condition>Insulin Sensitivity</condition>
  <condition>Oxidative Stress</condition>
  <arm_group>
    <arm_group_label>Galantamine then Placebo, WW</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4 mg (1 capsule) galantamine twice a day for 4 weeks then placebo (1 capsule) twice a day for 4 weeks in white women (WW)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo then Galantamine, WW</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (1 capsule) twice a day for 4 weeks then 4 mg (1 capsule) galantamine twice a day for 4 weeks in white women (WW)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Galantamine then Placebo, AAW</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4 mg (1 capsule) galantamine twice a day for 4 weeks then placebo (1 capsule) twice a day for 4 weeks in African American Women (AAW)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo then Galantamine, AAW</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (1 capsule) twice a day for 4 weeks then 4 mg (1 capsule) galantamine twice a day for 4 weeks African American Women (AAW)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Galantamine</intervention_name>
    <description>Galantamine 4 mg twice a day for 4 weeks</description>
    <arm_group_label>Galantamine then Placebo, WW</arm_group_label>
    <arm_group_label>Placebo then Galantamine, WW</arm_group_label>
    <arm_group_label>Galantamine then Placebo, AAW</arm_group_label>
    <arm_group_label>Placebo then Galantamine, AAW</arm_group_label>
    <other_name>Razadyne</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo 1 capsule twice a day for 4 weeks</description>
    <arm_group_label>Galantamine then Placebo, WW</arm_group_label>
    <arm_group_label>Placebo then Galantamine, WW</arm_group_label>
    <arm_group_label>Galantamine then Placebo, AAW</arm_group_label>
    <arm_group_label>Placebo then Galantamine, AAW</arm_group_label>
    <other_name>Razadyne</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  Female

          -  African American or white (race will be self-defined, but only subjects who report
             both parents of the same race will be included)

          -  18-60 years old

          -  BMI 30-45 Kg/m2

          -  Not pregnant or breastfeeding

        Exclusion Criteria

          -  Pregnant or breastfeeding

          -  Diabetes diagnosis (defined by the American Diabetes Association (ADA) criteria)38

          -  Cardiovascular disease such as myocardial infarction within 6 months prior to
             enrollment, presence of angina pectoris, significant arrhythmia, congestive heart
             failure (LV hypertrophy acceptable), deep vein thrombosis, pulmonary embolism, mitral
             valve stenosis, aortic stenosis, or hypertrophic cardiomyopathy.

          -  Arrhythmia (first-, second-, and third-degree AV block)

          -  Significant weight change &gt;5% in the past 3 months

          -  Impaired hepatic function (AST and/or ALT &gt;1.5X upper limit of normal range)

          -  Impaired renal function (eGFR &lt;60ml/min)

          -  Users of strong inhibitors of CYP3A4 or CYP2D6

          -  Users of other acetylcholinesterase inhibitors such as pyridostigmine or bethanechol

          -  History of alcohol or drug abuse

          -  Mental conditions rendering the subject unable to understand the nature, scope, and
             possible consequences of the study

          -  Inability to comply with the protocol, e.g., uncooperative attitude, inability to
             return for follow-up visits, and unlikelihood of completing the study

          -  Steroid use within 6 weeks prior to study entry

          -  Any underlying or acute disease requiring regular medication which could possibly pose
             a threat to the subject or make implementation of the protocol or interpretation of
             the study results difficult

          -  Discretion of the investigator
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cyndya A Shibao, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt University Medical Center, Clinical Pharmacology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Cyndya Shibao, RN</last_name>
    <email>cyndya.shibao@vanderbilt.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Cyndya A Shibao, MD</last_name>
    <email>cyndya.shibao@vanderbilt.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cyndya Shibao</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37027</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cyndya Shibao, RN</last_name>
      <email>cyndya.shibao@vanderbilt.edu</email>
    </contact>
    <investigator>
      <last_name>Cyndya A Shibao, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 3, 2017</study_first_submitted>
  <study_first_submitted_qc>January 6, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 9, 2017</study_first_posted>
  <last_update_submitted>January 23, 2018</last_update_submitted>
  <last_update_submitted_qc>January 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 25, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt University Medical Center</investigator_affiliation>
    <investigator_full_name>Cyndya Shibao</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>insulin sensitivity</keyword>
  <keyword>African American</keyword>
  <keyword>obese</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypersensitivity</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Galantamine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>No sharing</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

